ARTICLE
3 October 2024

Senator Wyden Proposes Legislation To Regulate Hemp-Derived Cannabis As Distinct Product Class

BI
Buchanan Ingersoll & Rooney PC

Contributor

With 450 attorneys and government relations professionals across 15 offices, Buchanan Ingersoll & Rooney provides progressive legal, business, regulatory and government relations advice to protect, defend and advance our clients’ businesses. We service a wide range of clients, with deep experience in the finance, energy, healthcare and life sciences industries.
Senator Wyden introduced legislation in an effort to create a new regulatory class of products that would consist of hemp-derived cannabis products. While products that are hemp-derived and have low
United States Cannabis & Hemp

Senator Wyden introduced legislation in an effort to create a new regulatory class of products that would consist of hemp-derived cannabis products. While products that are hemp-derived and have low levels of delta-9 THC are not regulated by the Drug Enforcement Administration, they can still be regulated by the Food and Drug Administration (FDA) as foods, dietary supplements, drugs, or medical foods. This proposed legislation would provide a new distinct regulatory class specifically for these products, allowing them to remain on the market under FDA regulation.

Senator Ron Wyden (D-Oregon) has introduced new legislation that would regulate the hemp-derived cannabinoid industry. The "Cannabinoid Safety and Regulation Act" would establish a regulatory regime for products that contain hemp cannabinoids. The law would require manufacturers to register with the U.S. Food and Drug Administration (FDA) and test their products for potency, pesticides, heavy metals, chemical byproducts, and additives. FDA will be tasked with developing rules for the manufacture and testing of these products. Additionally, the law would set a federal age limit of 21 on hemp-derived products, and prohibit the sale of synthetic cannabinoids. Labeling and packaging requirements will also be established to ensure that products are not designed to appeal to children, and accurately convey potency, risks of consumption, and lack of FDA review or approval.

www.cannabissciencetech.com/...

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Find out more and explore further thought leadership around Cannabis & Hemp

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More